Researchers link elevated Lipoprotein(a) to higher cardiovascular and stroke risk
Updated
Updated · SciTechDaily · May 4
Researchers link elevated Lipoprotein(a) to higher cardiovascular and stroke risk
8 articles · Updated · SciTechDaily · May 4
In 20,070 NIH trial participants aged 40 and older, Lp(a) levels of at least 175 nmol/L were tied to 31% higher major event risk and 49% higher cardiovascular death risk.
Over nearly four years, 1,461 major events occurred; stroke risk rose 64%, while heart attack risk did not, and the association was stronger in patients with existing heart disease.
Presented at the SCAI and CAIC-ACCI meeting in Montreal, the findings suggest a simple blood test could identify inherited residual risk as targeted Lp(a) treatments are developed.
Your genes say high heart risk, but your artery scans are clear. Will you still need the next generation of cholesterol drugs?
A silent killer affects one in five people. With targeted drugs on the horizon, is it time for universal screening?
Universal One-Time Lp(a) Screening in 2026 ACC/AHA Guidelines: Defining Extremely High Risk at ≥175 nmol/L
Overview
The 2026 ACC/AHA guidelines introduce universal one-time screening for lipoprotein(a) [Lp(a)] in all adults, recognizing its strong genetic basis and stable lifelong levels. Elevated Lp(a), especially above 175 nmol/L, significantly increases the risk of heart attack, stroke, and valve disease by promoting artery inflammation and blood clotting. Incorporating Lp(a) into the new PREVENT-ASCVD risk calculator enables personalized prevention, with aggressive LDL cholesterol lowering for those at high risk. Emerging RNA-based and oral therapies promise dramatic Lp(a) reductions, though high costs and global access disparities remain challenges. Supported by cost-effectiveness evidence and global policy initiatives, this shift marks a new era in precision cardiovascular care.